Cubist Systematic Strategies’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Cubist Systematic Strategies’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-38,005	Closed	-$68K	–	4790
2022 Q3	$68K	Sell	38,005 -566	-1%	-$1.64K	﹤0.01%	4087
2022 Q2	$112K	Sell	38,571 -25,940	-40%	-$64K	﹤0.01%	3937
2022 Q1	$178K	Sell	64,511 -34,294	-35%	-$108K	﹤0.01%	3085
2021 Q4	$460K	Buy	98,805 +32,078	+48%	+$201K	﹤0.01%	2505
2021 Q3	$568K	Buy	66,727 +35,298	+112%	+$499K	0.01%	1947
2021 Q2	$516K	Buy	31,429 +835	+3%	+$16.9K	0.01%	1990
2021 Q1	$676K	Buy	30,594 +22,857	+295%	+$623K	0.01%	1785
2020 Q4	$239K	Buy	+7,737	New	+$196K	﹤0.01%	2147

Other funds holding TCRR

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Cubist Systematic Strategies's TCRR Position: Q4 2022 in Review

Cubist Systematic Strategies sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2022, closing a stake of 38,005 shares — an estimated $68K sold.

Cubist Systematic Strategies first reported a position in TCRR in Q4 2020 and held it in 8 quarters. The position peaked at $676K in Q1 2021. 63 funds tracked by Wall St. Rank hold TCRR as of Q4 2022.

Cubist Systematic Strategies reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Cubist Systematic Strategies sold 38,005 TCR2 Therapeutics Inc. Common Stock shares in Q4 2022, an estimated $68K.
Cubist Systematic Strategies first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2020 and held it in 8 quarters.
Cubist Systematic Strategies's TCR2 Therapeutics Inc. Common Stock position peaked at $676K in Q1 2021.
63 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2022.

Based on Cubist Systematic Strategies's 13F filing for Q4 2022, filed 14 Feb 2023.